vTv Therapeutics Inc. Stock Price

NasdaqCM:VTVT Community·US$197.1m Market Cap

0 Narratives written by author
0 Comments on narratives written by author
0 Fair Values set on narratives written by author

Create a narrative

VTVT Share Price Performance

US$24.24

10.41 (75.33%)

US$24.24

10.41 (75.33%)

US$24.24

Thu, 6 Nov 25

Share PriceUS$24.24

VTVT Community Narratives

There are no narratives available yet.

Create a narrative

There are no community narratives available.

Snowflake Analysis

Flawless balance sheet with low risk.

3 Risks

0 Rewards

View Full Analysis

vTv Therapeutics Inc. Key Details

Last Reported Earnings

Jun 30, 2025

Next Reporting Earnings

n/a

: -2.47
: -69,294.12%
: -115,029.41%
: 0%

View Full Analysis

About VTVT

Founded: 2015
Employees: 23
CEO: Paul Sekhri
WebsiteView website: vtvtherapeutics.com

vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company is also investing a range of molecules across various indications for chronic diseases. It has a license agreement Newsoara Biopharma Co., Ltd. to develop and commercialize phosphodiesterase type 4 inhibitors program. The company was incorporated in 2015 and is headquartered in High Point, North Carolina.